Lazard Asset Management
CRSP icon

Lazard Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Lazard Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Sell
47,065
-3,181
-6% -$168K ﹤0.01% 840
2025
Q4 		$2.63M Sell
50,246
-8,080
-14% -$484K ﹤0.01% 758
2025
Q3 		$3.78M Sell
58,326
-1,007
-2% -$57.8K 0.01% 654
2025
Q2 		$2.88M Sell
59,333
-4,357
-7% -$169K ﹤0.01% 892
2025
Q1 		$2.17M Sell
63,690
-7,333
-10% -$311K ﹤0.01% 947
2024
Q4 		$2.79M Sell
71,023
-14,254
-17% -$673K ﹤0.01% 775
2024
Q3 		$4M Buy
85,277
+11,074
+15% +$562K 0.01% 692
2024
Q2 		$4.01M Sell
74,203
-11,937
-14% -$690K 0.01% 734
2024
Q1 		$5.87M Sell
86,140
-10,940
-11% -$783K 0.01% 653
2023
Q4 		$6.08M Sell
97,080
-18,434
-16% -$1.02M 0.01% 648
2023
Q3 		$5.24M Sell
115,514
-3,338
-3% -$172K 0.01% 688
2023
Q2 		$6.67M Sell
118,852
-4,937
-4% -$280K 0.01% 642
2023
Q1 		$5.6M Buy
123,789
+1,434
+1% +$69.6K 0.01% 701
2022
Q4 		$4.97M Sell
122,355
-103,369
-46% -$5.48M 0.01% 719
2022
Q3 		$14.8M Sell
225,724
-38,403
-15% -$2.78M 0.02% 491
2022
Q2 		$16.1M Buy
264,127
+90,940
+53% +$5.35M 0.02% 490
2022
Q1 		$10.9M Buy
173,187
+42,369
+32% +$2.66M 0.01% 588
2021
Q4 		$9.91M Buy
130,818
+72,555
+125% +$6.34M 0.01% 630
2021
Q3 		$6.52M Buy
58,263
+2,734
+5% +$343K 0.01% 698
2021
Q2 		$8.99M Buy
55,529
+54,755
+7,074% +$6.66M 0.01% 621
2021
Q1 		$94K Sell
774
-76
-9% -$11.5K ﹤0.01% 1217
2020
Q4 		$130K Buy
+850
New +$100K ﹤0.01% 1145
2020
Q2 		– Sell
-1,498
Closed -$63K – 1631
2020
Q1 		$63K Buy
+1,498
New +$77.3K ﹤0.01% 1107

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lazard Asset Management's CRSP Position: Q1 2026 in Review

Lazard Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 6.3% in Q1 2026, selling an estimated $168K and leaving 47,065 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #840.

Lazard Asset Management first reported a position in CRSP in Q1 2020 and has held it in 23 quarters since. The position peaked at $16.1M in Q2 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Lazard Asset Management held 47,065 shares of CRISPR Therapeutics worth $2.24M as of Q1 2026.
  • Lazard Asset Management sold 3,181 CRISPR Therapeutics shares in Q1 2026, an estimated $168K.
  • CRISPR Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #840 holding.
  • Lazard Asset Management first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Lazard Asset Management's CRISPR Therapeutics position peaked at $16.1M in Q2 2022.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.